dslogo
azlogo

Progression-Free Survival

Progression-Free Survival1,21.Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [article]. N Engl J Med. 2022;387:9-202.Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [supplementary appendix]. N Engl J Med. 2022;387:9-20.

Overall Survival

Overall Survival1,21.Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [article]. N Engl J Med. 2022;387:9-202.Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [supplementary appendix]. N Engl J Med. 2022;387:9-20.

Confirmed Objective Response Rate and Best Overall Response

Confirmed Objective Response Rate and Best Overall Response11.Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [article]. N Engl J Med. 2022;387:9-20

Confirmed ORR and Best Overall Response.11.Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [article]. N Engl J Med. 2022;387:9-20
 HR+25.  All Patients (HR+ and HR−)HR-25.  

T-DXd

(n=333)

TPC

(n=166)

T-DXd

(n=373)

TPC

(n=184)

T-DXd

(n=40)

TPC

(n=18)

Confirmed ORR, n (%) [95% CI]

175 (52.6)

[47.0-58.0]

27 (16.3)

[11.0-22.8]

 

195 (52.3)

[47.1-57.4]

 

30 (16.3)

[11.3-22.5]

 

20 (50.0)

[33.8-66.2]

 

3 (16.7)

[3.6-41.4]

CR12 (3.6)1 (0.6)13 (3.5)2 (1.1)1 (2.5)1 (5.6)
PR164 (49.2)26 (15.7)183 (49.1)28 (15.2)19 (47.5)2 (11.1)
SD117 (35.1)83 (50.0)129 (34.6)91 (49.5)12 (30.0)8 (44.4)
PD26 (7.8)35 (21.1)31 (8.3)41 (22.3)5 (12.5)6 (33.3)
Not evaluable14 (4.2)21 (12.7)17 (4.6)22 (12.0)3 (7.5)1 (5.6)
DCR (CR + PR + SD), n (%)293 (88.0)110 (66.3)325 (87.1)121 (65.8)32 (80.0)11 (61.1)

Clinical benefit rate25.  , n (%)

237 (71.2)57 (34.3)262 (70.2)62 (33.7)25 (62.5)5 (27.8)
Median DoR, months10.76.810.76.88.64.9
Median time to response, months2.762.732.732.221.511.41
1Hormone receptor status is based on data from the electronic data capture corrected for mis-stratification; 2The clinical benefit rate is defined as the sum of complete response, partial response, and more than 6 months’ stable disease, based on blinded independent central review.

Best change in Target Lesions (All Patients)

Best Change in Target Lesions (All Patients)22.Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [supplementary appendix]. N Engl J Med. 2022;387:9-20.

Best change in Target Lesions (All Patients)22.Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [supplementary appendix]. N Engl J Med. 2022;387:9-20.

Best change in Target Lesions (All Patients)22.Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [supplementary appendix]. N Engl J Med. 2022;387:9-20.

Abbreviations

CR = complete response

;

DCO = data cut-off

;

DCR = disease control rate

;

DoR = duration of response

;

HR = hormone receptor

;

IHC = immunohistochemistry

;

ISH = in situ hybridization

;

mo = months

;

mOS = median overall survival

;

mPFS = median progression-free survival

;

NE = not evaluable

;

ORR = objective response rate

;

OS = overall survival 

;

PD = progressive disease

;

PFS = progression-free survival 

;

PR = partial response 

;

SD = stable disease

;

T-DXd = trastuzumab deruxtecan

;

TPC = treatment of physician's choice

References

1. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [article]. N Engl J Med. 2022;387:9-20
2. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [supplementary appendix]. N Engl J Med. 2022;387:9-20.

Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy. 

To help us improve our content for health care professionals, please take this short survey.

Feedback Survey

©2023 AstraZeneca. All rights reserved.